AOD 9604 – Growth Hormone Fragment Research Peptide

1. Product Overview

AOD 9604 is a synthetic peptide fragment derived from the C‑terminal region of human growth hormone (hGH), corresponding to the 176–191 segment with specific sequence modifications. It is engineered to isolate metabolically relevant actions of the hGH C‑terminus, with a focus on adipocyte and lipid metabolism, while minimizing broader growth hormone–like effects.

In research settings, AOD 9604 is commonly used to study:

• Adipocyte lipid mobilization and storage dynamics
• Energy balance and body-composition–related signaling pathways
• Structure–function relationships of growth hormone fragments
• Distinct downstream signaling profiles compared to full-length hGH

For research use only. Not for human or veterinary use.

2. Mechanistic Profile

AOD 9604 is a growth hormone–derived fragment designed to capture the activity associated with the C‑terminal portion of hGH, particularly in the context of fat metabolism and energy regulation. It is generally investigated for fragment-selective activity rather than broad GH receptor agonism.

Fragment-Associated Metabolic Cascade (Conceptual)

Based on preclinical and in vitro data, AOD 9604 is thought to:

1. Engage signaling pathways influenced by the C‑terminal hGH domain.
2. Modulate intracellular networks associated with lipid metabolism (including lipolysis–lipogenesis balance) in adipocytes.
3. Impact kinase- and possibly cAMP-linked pathways in a manner distinct from full-length GH (mechanism may be indirect or context-dependent).
4. Favor enhanced lipid turnover and/or altered fat storage patterns in certain models.
5. Exhibit reduced activation of classical GH–IGF‑1 axes relative to intact hGH, as reported in some research contexts.

This mechanistic profile underpins its role in:

• Studies of selective modulation of hGH-related functions
• Research on endocrine and metabolic control of adipose tissue
• Investigations into energy homeostasis and GH fragment pharmacology

Mechanistic descriptions refer to experimental and preclinical research and are not claims of clinical outcome.

3. Structural & Chemical Data

• Peptide Type: Synthetic C‑terminal fragment of human growth hormone (176–191 region)
• Class: Short linear peptide (GH fragment analog)
• Origin Concept: Derived from human pituitary growth hormone sequence with targeted modifications

Typical attributes:

• Peptide Length: Short fragment (approx. 15–20 amino acids, depending on specific analog design)
• Approximate Molecular Mass: In the ~1.5–2.0 kDa range (exact mass defined per sequence)

AOD 9604 is designed to:

• Preserve C‑terminal domain features implicated in fat and energy metabolism
• Limit broader anabolic and mitogenic activities characteristic of full-length hGH

Exact amino acid sequence, molecular weight, and related specifications should be confirmed in the lot-specific Certificate of Analysis (CoA).

4. Analytical Characterization (HPLC / MS)

HPLC

• AOD 9604 is typically purified to ≥ 98 % by High-Performance Liquid Chromatography (HPLC).
• HPLC profiles (retention time, peak purity) are verified against validated peptide standards for each batch.

MS

• Identity is confirmed by mass spectrometry (MS or LC‑MS):
• Observed molecular ion matches the theoretical mass for the specific AOD 9604 sequence.
• Fragmentation spectra may be used to confirm sequence and structural integrity.

This analytical characterization supports its use in:

• Mechanistic cell-based and biochemical assays
• Structure–activity relationship (SAR) analysis of GH fragments
• Development and validation of GH fragment–specific analytical methods

5. Key Research Uses

5.1 Adipocyte Metabolism & Lipid Dynamics

In preclinical models, AOD 9604 is employed to:

• Examine lipid turnover in adipocytes under controlled conditions
• Study the balance between lipolysis and lipogenesis in response to GH-derived fragments
• Assess how C‑terminal GH peptides affect fat cell function independent of full-length GH

Research focus includes:

• Alterations in lipid-handling enzymes and transporters
• Downstream metabolic signaling related to fat storage and mobilization

5.2 Energy Expenditure & Metabolic Regulation

AOD 9604 is used as a probe in models exploring:

• Energy expenditure, substrate utilization, and caloric balance
• Interactions between GH fragments and metabolic signaling networks
• Potential fragment-specific modulation of glucose and lipid homeostasis in vitro and in animal models

This work often involves:

• Comparing full-length hGH versus GH fragments
• Profiling pathways using omics and targeted signaling analyses

5.3 Growth Hormone Fragment Structure–Function Mapping

Given its C‑terminal origin, AOD 9604 is a valuable tool in:

• Structure–function studies of GH fragments
• Dissecting which regions of hGH are crucial for metabolic vs. growth-related effects
• Comparing different GH-derived peptides for receptor interaction and downstream signaling

These studies can:

• Inform rational design of second-generation GH fragment analogs
• Clarify the functional domains responsible for adipocyte-specific outcomes

5.4 Peptide Pharmacology, Stability & Assay Development

AOD 9604 is also useful as a model compound in:

• Peptide stability and degradation studies (e.g., protease susceptibility, half-life in different matrices)
• Method development for quantitative peptide assays (LC‑MS/MS, ELISA, etc.)
• Research on peptide formulation behaviors, including solubility and adsorption to lab plastics or glass

Note: AOD 9604 is made available exclusively for laboratory research use. It is not intended for medicinal, diagnostic, or veterinary applications.

6. Storage – Sublimated AOD 9604

6.1 Vacuum Sublimation & Shipping

AOD 9604 is produced as a sublimated peptide powder using a Vacuum Sublimation (Controlled Dehydration) process.

Vacuum sublimation (controlled sublimation):

• The peptide is frozen under controlled conditions.
• It is then exposed to reduced atmospheric pressure.
• Water in the peptide matrix transitions directly from the solid phase to the vapor phase.
• This yields a stable, amorphous powder structure referred to as a sublimated peptide.

In this state:

• AOD 9604 remains completely stable for shipping for approximately 4–6 months, provided it is protected from heat and humidity.

The sublimated powder can be stored at ambient laboratory temperature until reconstitution with sterile phosphate buffer, following good storage practice.

6.2 Storage Before Reconstitution

Upon receipt, AOD 9604 should be kept under controlled environmental conditions and protected from humidity.

Recommended conditions:

• Short- to mid-term (days → several weeks/months):
• Refrigerated storage at 2–4°C is generally suitable.
• Sublimated peptides are typically stable at room temperature for 4–6 weeks or more, if kept dry and away from light.
• If the peptide will not be reconstituted within 5–7 weeks, refrigeration at 2–4°C is preferred.
• Long-term (8 months → 3 years):
• Store in a cryogenic freezer at -70°C (-94°F).
• For multi‑month or multi‑year storage, cryogenic preservation is recommended to maintain structural stability and minimize degradation.

6.3 Storage After Reconstitution

Once AOD 9604 has been reconstituted with sterile phosphate buffer:

• Store the solution at 2–4°C.
• Under these refrigerated conditions, reconstituted peptide is typically stable for up to 14 days.

Best practices:

• Limit storage time in solution; keep the bulk of the material in dry sublimated form whenever possible.
• Confirm solution stability under your specific buffer conditions, concentration, and experimental protocol.

7. Handling & Best Practices

7.1 General Handling

• Store AOD 9604 in a cool, dry, dark location.
• Avoid repeated freeze–thaw cycles by preparing small aliquots.
• Minimize exposure to ambient moisture; keep vials tightly capped.
• Protect from direct light, particularly strong visible or UV light.

7.2 Preventing Humidity & Oxidative Degradation

• After removing vials from refrigeration or cryogenic storage, let them reach room temperature before opening to prevent condensation.
• Keep containers closed as much as possible; reseal immediately after each use.
• When feasible, maintain residual powder under a dry, inert gas (e.g., nitrogen or argon).
• Use pre-divided aliquots to reduce handling, air exposure, and temperature cycling.

7.3 Storage in Solution

• Peptide solutions are more fragile than dry powders and have a shorter shelf life.
• If solution storage is necessary:
• Use sterile phosphate buffer (as specified) or another sterile buffer compatible with your assay.
• Store at 2–4°C and use within 14 days, unless more extensive stability data are available.
• Prepare small-volume aliquots to avoid repeated freeze–thaw of the same tube.

7.4 Storage Containers

• Storage vials should be:
• Clean, low-binding, and chemically inert
• Sized appropriately to minimize headspace and moisture ingress
• Common options:
• Glass vials – excellent chemical inertness; often preferred for long-term storage.
• Polypropylene vials – durable, chemically resistant, and widely used for peptide storage.

Transfer between container types (e.g., shipping plastic → glass storage) may be carried out under appropriate sterile and low-humidity conditions.

8. Scientific Context & Acknowledgment

AOD 9604 is part of a broader research effort to dissect the domain-specific activities of human growth hormone, particularly those related to adipose tissue biology and metabolic control. Studies of GH fragments, including AOD 9604, have:

• Helped differentiate growth-promoting vs. metabolically oriented effects of hGH
• Contributed to understanding which sequences of GH are responsible for lipid-related outcomes
• Provided model compounds for exploring selective modulation of GH-related pathways

This context is provided solely to situate AOD 9604 within the scientific literature on GH fragments and metabolic peptide research.
It is not intended as clinical guidance or promotion.
No affiliation, endorsement, or sponsorship by any specific investigator, institution, or publication is implied.

9. Notes on Literature & References

Scientific literature relating to AOD 9604 and GH fragments can be found in journals covering:

• Endocrinology and metabolism
• Peptide and protein pharmacology
• Adipocyte and obesity research
• Hormone signaling and receptor pharmacology

Researchers can search databases such as PubMed, Scopus, or Web of Science using terms like:

• “AOD 9604 peptide”
• “growth hormone fragment 176–191”
• “GH fragment adipocyte metabolism”
• “growth hormone C-terminal fragment metabolic effects”

to identify relevant preclinical and clinical studies aligned with their experimental focus.